Research Article

Interleukin-22 Ameliorates Dextran Sulfate Sodium-Induced Colitis through the Upregulation of IncRNA-UCL to Accelerate Claudin-1 Expression via Sequestering miR-568 in Mice

Chonghua He, Zehan Chen, Jialan Huang, Riyun Gan, Jianyao Wang, Lisheng Wang, Defeng Li, and Jun Yao

1Department of Gastroenterology, Shenzhen People’s Hospital, Jinan University of Second Clinical Medical Sciences, No. 1017 East Gate Road, Luohu District, Shenzhen, 518020, Guangdong Province, China
2Department of General Surgery, Shenzhen Children’s Hospital, Shenzhen 518026, Guangdong Province, China

Correspondence should be addressed to Defeng Li; ldf730712@163.com and Jun Yao; yj_1108@126.com

Received 27 July 2022; Revised 3 August 2022; Accepted 5 August 2022; Published 31 August 2022

Academic Editor: Tarique Hussain

Copyright © 2022 Chonghua He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Bioactive compound such as interleukin-22 (IL-22) treatment is regarded as a sufficient treatment for ulcerative colitis (UC). It has been found that long noncoding RNAs (lncRNAs) expressed in many inflammatory diseases, including UC.

We aimed to verify the treatment effect of bioactive compounds including IL-22 and lncRNAs in UC on colitis mice. Methods. UC mice were induced using DSS, followed by IL-22 or PBS intraperitoneally (i.p.) injection. Then, the histopathological parameters of the mice were determined. Then, RNA sequencing was performed to screen the differential lncRNAs. Quantitative real-time PCR (qRT-PCR) and lentivirus identified IncRNA-Ulcerative Colitis IncRNA (IncRNA-UCL) were regarded as the molecular regulator of the colitis mice. The correlation with IncRNA-UCL and mmu-miR-568 was validated using RNA-pulldown. Meanwhile, claudin-1 was predicted and confirmed as the target molecule of mmu-miR-568 using dual-luciferase assay. Results. IL-22 could significantly improve the histopathological features and decrease proinflammatory cytokine production in UC mice induced by DSS. It also can stimulate intestinal epithelial cell (IEC) reproduction and prevention of apoptosis. IncRNA-UCL was significantly downregulated in UC mice caused by DSS, while IL-22 treatment effectively reversed this effect. In terms of mechanism, IncRNA-UCL regulates intestinal epithelial homeostasis by sequestering mmu-miR-568 and maintaining tight junction (TJ) protein.

Conclusions. We have demonstrated the incredible role of bioactive compound, such as IL-22, in alleviating DSS-induced colitis symptoms via enhancing IncRNA-UCL expression. It can be regulated using tight junction (TJ) protein.

1. Introduction

UC is a major type of inflammatory bowel disease (IBD), which is a chronically recurring and relatively intractable IBD. The typical symptom of UC patients includes bloody diarrhea, mucus discharge, abdominal pain, and weight loss, which greatly impair the patient’s life quality and has become a health challenge worldwide [1–3]. Many studies have suggested that hereditary factors, immunological dysregulation and environmental aspect, may be causative factors for UC [4–6]. However, pathogenesis of UC remains largely unknown [7]. The frequency of UC has increased rapidly in Asia over the past few decades [1, 8]. The number of medical approaches available for UC is limited [9–12]. Accordingly, it is highly needed to develop new and effective treatment options for UC patients.

Bioactive compound has been universally used in many diseases such as UC. IL-22 is a kind of bioactive compound vest in IL-10, which is characterized by their intestinal homeostasis maintenance and IEC barrier functions [13–15]. IL-22 is primarily generated by immune cells on mucosal surfaces. IL-22 plays crucial roles in maintaining the epithelial integrity of the intestinal tract and protection of the intestine from toxic stress and pathogens, by activating of signal transducer and
activator of transcription 3 (STAT3) signaling [16–19]. It has been well documented that IL-22 can increase IEC viability and reversal of IEC damage, as a result of IBD and graft-versus-host disease (GVHD) [20, 21]. However, controlling the dosage is quite important. Studies have found IL-22 can promote IBD development and tumorigenesis in mouse models if IL-22 is not properly controlled [22, 23], implying that IL-22 signaling should be correctly regulated to facilitate the maintenance of IEC integrity.

Long noncoding RNAs (lncRNAs) with a length of about 200 nucleotides could extensively involve in many types of crucial biological and physiological processes such as cell proliferation, metabolism, differentiation, and immunity. The upregulation and downregulation of lncRNAs are both closely related to the occurrence and metastasis of tumors, cardiovascular disorder, nervous diseases, gastrointestinal diseases, and some other diseases. Therefore, the usage of lncRNAs as markers or targets of various diseases can provide new solutions into the diagnosis and treatment. Numerous studies have shown that lncRNA dysregulation is highly relevant with the onset and advancement of many diseases, including IBD [24–26]. It has been found that the upregulation of H19 is required for IEC multiplication and mucosal healing in cell cultures and inflammatory mouse models [27]. Another study demonstrated that lncRNA uc.173 could contribute to intestinal mucosa regulation and reproduction [28]. lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) showed important function in intestinal mucosa equilibrium. If MALAT1 downregulated, they contributed to IBD pathogenesis by disrupting TJs in DSS-induced experimental colitis [29]. These findings demonstrated the incredible function of lncRNAs in IBD pathogenesis.

Nonetheless, the lncRNA mechanism of IL-22-induced inflammation in UC remains unknown. Therefore, there is an urgent need to explore the features of lncRNAs on the intestinal epithelium in colitis under the effect of IL-22. Accordingly, we first estimated the therapeutic effect of IL-22 on DSS-induced colitis in mice. In addition, the potential mechanisms were explored in DSS-induced colitis mice, mainly at the UC-affected sites.

2. Materials and Methods

2.1. Ethics Statement. This study strictly implements the principles of the China Laboratory Animal Guideline for Ethical Review of Animal Welfare (GB/T 35892-2018), and all experiments performed on animals got approval from the Medical Ethics Committee of China Shenzhen People’s Hospital.

2.2. DSS-Induced Colitis Model and IL-22 Treatment. 10-week male C57BL/6j mice were used in our study. All the mice were kept in specific pathogen-free environment. The mice were randomly divided into three groups with 9 mice in the control group (fed using water for 12 days), and 15 mice were treated by DSS with PBS, while other 15 mice were treated using DSS and IL-22. The other two groups were firstly administrated with 3% DSS (36-50 kDa; MP Biomedicals, USA) for 8 days to establish the colitis model. Then, the DSS+PBS group was fed with PBS for 9 days at the 4th day of model establishment. The DSS+IL22 group was treated using recombinant IL-22 (rIL-22, PeproTech) daily for 9 days using i.p. injection.

2.3. Mouse Tissue Processing and Histopathological Evaluation. We recorded weight loss, change in consistency of stool, and severe bleeding parameters to determine the disease activity index (DAI). DAI was determined by the degree of diarrhea and visible fecal blood, together with the severity of colitis, which was evaluated daily through the determination of weight loss and DAI [30]. After euthanasia, the entire colon, containing caecum to anus, and small intestine were excised from each of the mice. The colon was collected to measure their length and separated for other tests, including immunohistochemistry (IHC), cytokine quantitation, identification of RNA and protein, and IEC isolation. On day 8, we also collected intestinal tissue for IEC isolation and further analysis.

2.4. RNA Extraction and Quantitative Reverse Transcription PCR (qRT-PCR). TRIzol reagent (Thermo Fisher Scientific, USA) was chosen to extract RNA from tissues according to the protocol. Complementary DNA (cDNA) was synthesized using RNeasy Mini Kit (TakaRa). SYBR Green Master Mix (TakaRa) was utilized to execute qRT-PCR on a LightCycler480 system (Roche). Target gene expression was normalized by glyceraldehyde-3-phosphate dehydrogenase (GADPH). The primer sequences we selected are recorded in Table 1.

2.5. Isolation and Culture of Mouse Colonic ECs. Colon tissues were removed from the mice and cleared by flushing using a syringe of cold PBS. Then, the colons were longitudinally opened and cut into small pieces less than 0.5 cm. The mixtures were incubated in a dissociation buffer at pH = 7.4 (10 mM EDTA, 1 mM DTT, 150 mM NaCl, and 10 mM HEPES) and 10% heat inactivated FBS at 37°C for 30 min. Thereafter, continuously shake the tubes to release of ECs, and the EC suspension was washed using cold PBS. Then, the ECs were collected through centrifugation and were used for further analysis [31].

2.6. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA kit (R&D Systems, USA) was used to measure the cytokine expression in colonic tissues. The cytokine consists of IL-1β, TNF-α, IL-17A, and IL-6. Total protein concentration can be used to normalize the cytokine value.

2.7. IHC and Immunofluorescence (IF). All tissues were first embedded in paraffin. Paraffin slides were dewaxed, dehydrated, and then subjected to antigen retrieval. After blocking with 5% bovine serum albumin (BSA), it was followed by incubating with primary antibody at 4°C overnight. After incubation, an EnVision™ Detection Kit (DAKO, Denmark) was used for staining. Briefly, 3,3′-diaminobenzidine tetrahydrochloride (DAB) staining and hematoxylin were performed to counterstain the nuclei.

For the IF analysis, the procedures were the same until primary antibody incubation. After it, secondary antibodies
Table 1: The primer sequences.

| Genes           | Sequences                  |
|-----------------|----------------------------|
| mTNF-α forward  | 5′-TTGTGTCATCACTGAAGTCC-3′ |
| mTNF-α reverse  | 5′-CCATAGATCTGATCGAG-3′   |
| mIL-1β forward  | 5′-GATGGAGGATATATCAAC-3′  |
| mIL-1β reverse  | 5′-ACGGCAAGGTATAGATT-3′   |
| mIL-6 forward   | 5′-TGGATCCGACTGCTTCC-3′   |
| mIL-6 reverse   | 5′-GGATCCGACTGCTTCC-3′    |
| miFN-γ forward  | 5′-AGGCAGTATCATCTATTGC-3′ |
| miFN-γ reverse  | 5′-GGATCCGACTGCTTCC-3′    |
| mIL-18 forward  | 5′-GACTTTTGCTCAATGCTGAG-3′|
| mIL-18 reverse  | 5′-GGATCCGACTGCTTCC-3′    |
| mIL-17A forward | 5′-TGGATCCGACTGCTTCC-3′   |
| mIL-17A reverse | 5′-TGGATCCGACTGCTTCC-3′   |
| mCXCL1 forward | 5′-GCTATAGATCTGATCGAG-3′  |
| mCXCL1 reverse  | 5′-GCTATAGATCTGATCGAG-3′  |
| mCCL2 forward  | 5′-GCTATAGATCTGATCGAG-3′  |
| mCCL2 reverse  | 5′-GCTATAGATCTGATCGAG-3′  |
| mClaudin-1 forward | 5′-GCTATAGATCTGATCGAG-3′  |
| mClaudin-1 reverse | 5′-GCTATAGATCTGATCGAG-3′ |
| mZO1 forward    | 5′-GCTATAGATCTGATCGAG-3′  |
| mZO1 reverse    | 5′-GCTATAGATCTGATCGAG-3′  |
| mE-cadherin forward | 5′-GCTATAGATCTGATCGAG-3′  |
| mE-cadherin reverse | 5′-GCTATAGATCTGATCGAG-3′  |
| mOccludin forward | 5′-GCTATAGATCTGATCGAG-3′  |
| mOccludin reverse | 5′-GCTATAGATCTGATCGAG-3′  |
| mGAPDH forward  | 5′-GCTATAGATCTGATCGAG-3′  |
| mGAPDH reverse  | 5′-GCTATAGATCTGATCGAG-3′  |

(Alex Fluor 488 and 594) were incubated at room temperature one more hour. Then, DAPI was used to stain the nuclei, and pictures were captured under a microscope (LSM760, Zeiss).

2.8. RNA Sequencing (RNA-seq). RNA extraction was finished, and its integrity and concentration were assessed. Then, the RNA library was constructed using a TruSeq RNA Sample Preparation Kit V2 (Illumina, San Diego, CA, USA). RNA-seq was performed on Illumina HiSeq 2500 machines (Illumina), followed by filtration of cleaning of samples. Then, the reads were illustrated on the Mus musculus reference genome (mm10). The fragments per kilobase of transcripts per million mapped (FPKM) values were used to calculate transcript expression levels. Differentially expressed genes (DEGs) among the different treatment groups were analyzed using CuffDiff in the Cufflinks package (P < 0.05 and log2 fold change > 2). Kyoto Encyclopedia of Genes and Genomes (KEGG) were figured out by the Database for Annotation, Visualization and Integrated Discovery (DAVID) v.6.8. The R software was used (http://www.r-project.org) to classify and draw the heatmap.

2.9. Western Blotting Analysis. Radio Immunoprecipitation Assay (RIPA) buffer was used with protease and phosphatase inhibitor cocktails (Roche) added to extract proteins. 10% SDS-PAGE was applied to isolate protein and then transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). 5% nonfat milk was used to block the membranes. Primary antibody incubation and horseradish peroxidase-conjugated secondary antibody (1:3000) incubation were followed. ECL Enhanced Kit (Pierce Chemical Co., Rockford, IL, USA) was used to amplify signals, and then, the signals were captured by an ChemiDoc Touch Imaging System (BioRad, USA).

2.10. Cell Culture. MODE-K and HEK-293T cells were got from Chinese Academy of Science (Shanghai, China). Medium for MODE-K cells was Dulbecco’s modified Eagle’s medium/F12 (DMEM/F12, Gibco), and for HEK-293T cells, it was DMEM. All cells were cultured with medium plus 10% FBS and 1% antibiotics.

2.11. Lentivirus Construction. Lentiviral vectors of sh-UCL and sh-NC containing a EGFP expression cassette were constructed and used to infect MODE-K cells. The lentiviral infected stable cell clones were selected using 5 μg/ml polybrene (Sigma). GFP-positive cells can be visualized using fluorescence microscope (Axio Observer Z1, Zeiss, Germany).

2.12. Cytoplasmic/Nuclear Fractionation. Cytoplasmic and Nuclear RNA Puriﬁcation Kit (Norgen Biotek, Canada) was selected to fractionate cytoplasmic and nuclear. Firstly, extract MODE-K cell RNA, and then, nuclear and cytoplasmic RNA was analyzed using qRT-PCR. U6 and GAPDH were used as the controls for the two parts, respectively.

2.13. RNA-Pulldown. MODE-K cells were lysed on ice by protecting protease and RNase (Thermo Fisher Scientiﬁc) for 30 min. Then, streptavidin agarose beads were added into total lysate at 4°C lasting 4 h while being centrifuged. After adding biotin-labeled lncRNA-UCL probes or negative control (NC) probes, the same procedure was executed in them. After washing with a lysis buffer, qRT-PCR was utilized to know miR-568 enrichment.

2.14. Transfection. The miR-568 mimic or inhibitor (GenePharma, China) was inserted into MODE-K cells by Lipofectamine 3000 (Invitrogen) system. 48 h after transfection, the efﬁciency of transfection was determined and the transfected cells were used in further experiments.

2.15. miRNA Target Prediction. The potential target genes of miR-568 were predicted using TargetScan (http://www.targetscan.org/) and miRDB (http://mirdb.org/mirdb/).

2.16. Dual Luciferase. HEK-293T cells were cotransfected with pmirGLO (NC, wt or mut) (RiboBio) and miR-568 age (P < 0.05 and log2 fold change > 2). Kyoto Encyclopedia of Genes and Genomes (KEGG) were figured out by the Database for Annotation, Visualization and Integrated Discovery (DAVID) v.6.8. The R software was used (http://www.r-project.org) to classify and draw the heatmap.
mimics or NC using a Lipofectamine 3000. The firefly luciferase gene pmirGLO-control (Promega) in vector was used as internal control to detect transfection efficiency. After 48h of transfection, firefly and Renilla luciferase values were figured out using a Dual-Luciferase Reporter System (Promega). Renilla luciferase activity was used to normalize the results.

2.17. 5-Ethynyl-2'-Deoxyuridine (EDU) Assay. After treatment, the MODE-K cells were cultured and incubated with EDU at concentration of 10 μM at 37°C lasting 3 h. First of all, fix the cells using 4% paraformaldehyde at 25°C half an hour. The cells were then washed and visualized using a Cell-Light EdU Apollo 567 In Vitro Kit (RíoBio, Guangdong, China). Finally, EDU-positive cells could be visualized and captured under a confocal laser microscope (LSM760, Zeiss).

2.18. Statistical Analysis. Data were presented as mean ± SEM, and Graph Prism 7 (GraphPad Software, San Diego, CA, USA) was utilized for further analysis. Student’s t-test or Mann-Whitney U test was chosen to distinguish whether there exist differences in all the groups. The aforementioned experiments were all duplicated three times. Statistical analysis was performed using the SPSS17.0 software (SPSS, Chicago, IL, USA). P value less than 0.05 was regarded to have a significant difference.

3. Results

3.1. IL-22 Decreases Clinical Disease Severity of DSS-Induced UC. First, an UC mouse model was induced by using 3% DSS. DSS was administered in mice for 8 days to construct the model. IL-22 or PBS was i.p. injected into mice from the 4th day of the model establishment. A significant body weight loss was recorded (Figure 1(a)). We captured the photos of colon to compare the colon morphology and colon length after DSS stimulation to know the IL-22 effect for colon inflammation. Our results showed that the colons were shortened significantly when induced using DSS compared to normal mice. While when DSS-induced mice got IL-22 administration, their colon length was much longer compared to those without treatment (P < 0.001; Figure 1(b)). If mice were injected with DSS, they will meet a higher death rate. However, IL-22 treatment will reverse the results, meaning longer survival rate after IL-22 treatment (Figure 1(c)). As the same time, DSS induced a body weight loss. IL-22 can keep mice at weight even after DSS injection. IL-22 treatment even will lead to an increasing trend for body weight (P < 0.001; Figure 1(d)). It has been reported that DAI will increase after inducing using DSS [31]. It was found that IL-22 treatment can reverse the DAI result, indicating without rectal bleeding and kept in normal stool harness (Figure 1(e)).

3.2. IL-22 Suppressed Proinflammatory Cytokine Production in DSS-Induced UC Mice. Whether IL-22 could affect the proinflammatory activities in DSS-induced UC mice is still unknown, qPCR and ELISA were carried out. In the DSS-induced UC group, the gene expression levels of major proinflammatory cytokines, including TNF-α, IL-1β, IL-6, interferon-gamma (IFN-γ), IL-18, IL-17A, CXCL1, and CCL2, were elevated, compared with control group mice, while this phenomena was changed if treated with IL-22 (Figure 2(a)). In addition, the results of TNF-α, IL-1β, IL-6, and IL-17A detected by ELISA increased significantly when induced by DSS, while IL-22 treatment could reduce the cytokine levels that for proinflammation (Figure 2(b)). Taken together, we demonstrated that IL-22 could secrete proinflammatory cytokines and gene expression. UC induced by DSS could be treated by IL-22 via stop proinflammation.

3.3. IL-22 Ameliorated Intestinal Barrier Integrity. It is known that impairment and interruption of epithelial integrity are characteristics of colitis [32]. It has also been reported that DSS could induce severe impairment of mouse colon morphology, while IL-22 treatment significantly enhanced the histological changes induced by DSS. The representative images are shown in Figure 3(a), which showed the beneficial effects of IL-22 treatment. Since TJ and adhesion junction (AJ) proteins play crucial roles in maintenance of intestinal balance and epithelial barrier function, IF and qRT-PCR analyses were carried out to determine the TJ and AJ molecule expression level after IL-22 treatment. As it is shown in Figure 3(b), the expression levels of claudin-1 and STAT3 protein reduced greatly in the DSS-induced colitis group, while IL-22 treatment was able to reverse this effect (Figure 3(b)). Next, TJ protein and E-cadherin levels were examined, as they are also essential for the regulation of epithelial integrity. We found that claudin-1, ZO-1, E-cadherin, and occludin-1 gene expression levels were all significantly downregulated by DSS, whereas treatment with IL-22 reversed this effect, leading to an increased expression of claudin-1, ZO-1, and E-cadherin (Figures 3(c)–3(f)). As we all known from the previous research, IEC apoptosis or cell death induced by DSS contributed to disruption of intestinal integrity [30, 33]. The cleaved caspase-3 and PCNA results in IHC analysis showed that DSS induced the apoptosis and suppressed the proliferation of intestinal epithelial cells. However, treatment with IL-22 downregulated the cleaved caspase-3 level while upregulated PCNA expression (Figures 3(g)–3(i)). Western blotting analysis results also showed that E-cadherin and occludin-1 protein expressed less after DSS induction, while treatment with IL-22 reversed this effect, which is similar with the previous experiment presented results (Figure 3(j)). Taken together, we further demonstrate IL-22 can alleviate DSS-induced damage by protecting damaged colon tissue by upregulating intestinal barrier-related molecule expression.

3.4. IL-22 Induced a Transcriptome Turnaround UC Mouse Colon. Numerous studies have shown that IncRNA is highly relevant with the onset of many diseases, including inflammation [34, 35]. To have a good command of knowledge of regulatory mechanism of IL-22 in DSS-induced UC mice, RNA-seq was performed to screen the differential IncRNA expression profiles in the mouse colon tissues obtained from the three groups of mice. Thousands of IncRNAs showed different expression analyzed by hierarchical clustering. We set the thresholds of log$_{2}$foldchange > 2.0, P value < 0.05, Oxidative Medicine and Cellular Longevity
PBS (i.p.) 9 days
IL-22 (i.p.) 9 days
3% DSS water 8 days
Water 4 days

Day 0 Day 4 Day 9 Day 12
Control Water 12 days
DSS PBS (i.p.) 9 days
3% DSS water 8 days Water 4 days
IL-22 IL-22 (i.p.) 9 days

Control DSS IL-22

Colon length (cm)

⁎⁎⁎

Time (days)

Percent survival (%)

0 2 4 6 8 10 12

0 30 60 90

DSS + PBS (n = 15)
DSS + PBS (n = 6)
Control (n = 9)
DSS + IL-22 (n = 15)

PBS/IL-22 (i.p.)

3% DSS water Water

Pontes % initial weight (%)

⁎⁎⁎

PBS/IL-22 (i.p.)

3% DSS water Water

Figure 1: Continued.
According to the results, 62 IncRNAs were elevated and 128 IncRNAs were denticulated in DSS group mice compared to controls. Meanwhile, we found 22 IncRNA upregulation and 30 IncRNA deregulation when comparing DSS groups with or without IL-22 treatment, which is shown on a heatmap (Figure 4(a)). KEGG pathway analysis was conducted to predict the signaling pathway that the differentially expressed genes were possible involved in (Figure 4(b)). The results showed that 5 IncRNAs were significantly downregulated in the DSS+PBS group mouse colon tissues comparing with those in control group mice but remarkably had recovered in DSS+IL-22 groups. Therefore, these 5 IncRNAs were chosen for further validation using mouse colon tissue obtained from the three group mice using qRT-PCR. We found that the expression of IncRNA NONMMUG038140 was almost the same with RNA-seq results. As a consequence, we named IncRNA NONMMUG038140 as Ulcerative Colitis IncRNA (IncRNA-UCL) and conducted further research on it in our study (Figure 4(c)).

3.5. IncRNA-UCL Located in the Cytoplasm and Interacts with mmu-miR-568. To learn more about the function and role of IncRNA-UCL in the regulation of DSS-induced colitis, the lentiviral vector containing its interfering sequence was constructed and its inhibitory efficiency was determined using qRT-PCR. As shown in Figure 5(a), the lentivirus could remarkably silence IncRNA-UCL expression, compared with lentiviral NC. It has been well established that IncRNAs regulate expression of genes through competitive endogenous RNA that is dependent on its location [36, 37]. Therefore, the subcellular location of IncRNA-UCL was determined using a cytoplasmic/nuclear isolation kit and analyzed using qRT-PCR. The results show that most IncRNA-UCL is localized in the cytoplasm while was in nucleus (Figure 5(b)). Next, microRNAs (miRNAs) that may potentially bind to IncRNA-UCL were predicted using bioinformatics tools (Figure 5(c)) and validated using qRT-PCR. As shown in Figure 5(d), IncRNA-UCL expression was inhibited by transfecting the lentivirus into MODE-K cells, and miR-568 was found to be significantly upregulated \((P < 0.01)\). To further confirm the interaction between IncRNA-UCL and miR-568, the results of the RNA-pulldown assays confirmed that IncRNA-UCL could directly bind to miR-568 in MODE-K cells (Figure 5(e)). Next, miR-568 expression was examined in mouse colon tissues obtained from the three groups. The results showed that miR-568 was upregulated during DSS induction, while its levels decreased after IL-22 treatment (Figure 5(f)), suggesting IncRNA-UCL and miR-568 were negative correlated.

3.6. Identification of the Target Gene of miR-568. To determine potential target genes of miR-568, two online databases (TargetScan and miRDB) were searched, and it was found that claudin-1 may be the gene targeting ability for miR-568 (Figure 6(a)). To verify the hypothesis, miR-568 mimics and inhibitors were synthesized and transfected into MODE-K cells. Western blotting analysis results showed that the miR-568 mimics downregulated claudin-1 protein expression, whereas the miR-568 inhibitor upregulated
claudin-1 protein expression, compared with miRNA-NC (Figure 6(b)). Then, targeting ability of claudin-1 for miR-568 was double confirmed using dual-luciferase assays. The results exhibited that miR-568 could suppress the fluorescence intensity of cells transfected with wild-type 3′-UTR of claudin-1 plasmids, compared with mutant 3′-UTR of claudin-1 plasmids (Figure 6(c)). We also detected changes in claudin-1 gene and protein expression situation in mouse colon tissues among the three groups using qRT-PCR, western blotting, and IHC analyses. The results showed that claudin-1 gene and protein expression significantly down-regulated by DSS, and all the results exhibited the same

**Figure 2:** IL-22 inhibited the expression of proinflammatory cytokines in DSS-induced colitis mice colons. qRT-PCR was performed to determine proinflammatory cytokine mRNA expression levels (TNF-α, IL-6, IL-1β, IFN-γ, IL-18, IL-17A, CXCL1, and CCL2) in colon tissue. (b) ELISA assay was used to detect levels of soluble TNF-α, IL-6, IL-1β, and IL-17 in the medium of the colon tissues. Data are presented as mean ± SEM. ***P < 0.001; **P < 0.01; *P < 0.05 using Student’s t-test.
Figure 3: Continued.
However, IL-22 treatment significantly alleviated and reversed this effect both on claudin-1 mRNA and protein expression (Figures 6(d)–6(f)).

3.7. Upregulation of lncRNA-UCL Induced by IL-22 Sequestered miR-568 by Enhancing Claudin-1 Expression. To learn more about the function and role of IL-22 and lncRNA-UCL in IECs, qRT-PCR was performed on MODE-K cells and the results showed that IL-22 could enhance lncRNA-UCL expression obviously. Meanwhile, knockdown of lncRNA-UCL expression could enhance pro-inflammatory cytokine expression, including TNF-α, IL-1β, and IL-6 at mRNA level. However, this effect was significantly inhibited by IL-22 (Figure 7(a)). The expression levels of intestinal epithelial marker proteins under the effect of IL-22 treatment were also explored. The results of western blotting and EDU analyses show that the knockdown of lncRNA-UCL downregulated the expression of claudin-1, ZO-1, E-cadherin, and phosphorylated STAT3 protein and inhibited MODE-K cell proliferation, while IL-22 produced an opposite effect: upregulation of claudin-1, ZO-1, E-cadherin, and phosphorylated STAT3 protein and increased proliferation of MODE-K cells (Figures 7(b) and 7(c)). To elucidate the role of miR-568 on the intestinal epithelial

![Figure 3: IL-22 enhances the expression of intestinal epithelial apical junction proteins. (a) HE staining demonstrated pathological changes of the colon tissue. (b) Immunofluorescent staining results compared changes in the expression levels of tight junction (claudin-1) and STAT3 proteins in colon tissues obtained from the control, DSS+PBS, and DSS+IL-22 groups of mice. (c–f) qRT-PCR was conducted to determine the expression of apical junction markers (E-cadherin, claudin-1, ZO-1, and occludin-1) at gene level in colon tissue. (g–i) Immunohistochemistry analysis examined the protein expression levels of intestinal apoptosis marker (cleaved caspase-3) and proliferation marker (PCNA). (j) Western blotting analysis was conducted to detect the expression levels of apical junction proteins (E-cadherin and occludin-1) in colon tissue. Data are presented as mean ± SEM. **P < 0.01; #P < 0.05 using Student’s t-test.](image)
miR-568 mimics were used and the results showed that miR-568 significantly suppressed the expression of claudin-1, ZO-1, E-cadherin, and phosphorylated STAT3 protein and inhibited MODE-K cell proliferation, compared to the mimics-NC (Figures 7(d) and 7(e)). Furthermore, our results also showed that the inhibition of miR-568 expression could upregulate the expression of claudin-1, ZO-1, E-cadherin, and phosphorylated STAT3 protein and promote MODE-K cell proliferation. However, the knockdown of lncRNA-UCL could simultaneously inhibit miR-568 expression and can partially release the inhibitory effect induced by the silencing of lncRNA-UCL, including recovery of the claudin-1, ZO-1, E-cadherin, and phosphorylated STAT3 protein expression and MODE-K cell proliferation.
**Figure 5: Continued.**

(a) Relative Lnc-UCL expression

(b) Distribution

(c) miRNA-3p Target sites for Lnc-UCL

(d) Relative miRNA gene expression
Taken together, our results indicate that lncRNA-UCL regulates IEC homeostasis via sequestering miR-568 through the targeting of claudin-1.

### 4. Discussion

Intestinal homeostasis is maintained by both the intestinal epithelial barrier and the mucosal immune system [39]. The intestinal epithelial barrier is a footstone in intestinal homeostasis by providing a physical barrier to defend against bacteria and pathogens, while maintaining appropriate immune responses [40]. Dysfunction of the epithelial barrier may trigger an excessive inflammatory response, resulting in abnormal elevation of proinflammatory cytokine levels, especially IL-1β, TNF-α, and IL-6, caused by intestinal epithelial injury and impaired epithelial regeneration and repair. Maintenance of epithelial integrity is dependent on the apical junction complex (AJC), which includes the expression of TJ and AJ protein expression, which form a functional and physical barrier to prevent antigenic penetration [29]. Previous studies have reported that the disruption of epithelial cell barrier integrity is a result of the decrease in TJ protein expression, including claudin-1, ZO-1, and occludin-1, is a common characteristic of patients with UC and other IBDs [38]. Thus, repair of injured epithelial barrier and reversal of unanticipated inflammation are effective strategies for UC treatment.

Previous studies have demonstrated that IL-22 is involved in immune diseases, such as psoriasis, systemic erythema, hepatitis and rheumatoid arthritis, and colitis [14, 21]. IL-22 was able to upregulate tight junction protein claudin-2 expression to promote pathogen clearance in an infectious enterocolitis mouse model [41]. Similarly, the knockdown of IL-22 resulted in aggravation of IEC injury in a *Citrobacter rodentium* infection mouse model [42]. Meanwhile, it has been suggested that IL-22 exhibited protective ability in regulation of gut inflammation by stimulating colon epithelial cell lines to produce IL-10 and SOCS3 to ameliorate DSS-induced colitis via upregulating claudin-2 expression [43].

It has been reported that bioactive compounds for colitis treatment have many advantages including reducing weight loss, exerting anti-inflammatory reaction, and colon histological damage. For example, it has been reported that thymoquinone, a bioactive compound from Dietary, had profound anti-inflammatory effects to colitis as it could stimulate the expression of the epithelial transcription factor PPAR-γ. Study had also shown that the bioactive compounds from Pale Ale Beer Powder attenuate experimental colitis in mice. Therefore, bioactive compounds for colitis
Figure 6: Claudin-1 is the direct target of miR-568 in intestinal epithelial cells. Sequence alignment showing the binding sites between miR-568 and the 3’-UTR of claudin-1 mRNA. (b) Western blot analysis was used to detect changes in claudin-1 protein expression under the effect of miR-568 mimics and inhibitor in MODE-K cells. (c) Luciferase assay of HEK-293T cells cotransfected with miR-568 mimics and wild-type or mutant 3’-UTR of the claudin-1 mRNA sequence. (d–f) qRT-PCR, western blotting, and immunohistochemistry analyses were conducted to determine claudin-1 expression levels in the colon tissues of all groups of mice. Data are presented as mean ± SEM. **P < 0.01; *P < 0.05 using Student’s t-test.
Figure 7: Continued.
treatment have great application potential and broad application space. Here we investigated the function and role of bioactive compound, IL-22, in a DSS-induced UC mouse model. We aimed to identify its underlying potential mechanism of action in intestinal epithelial barrier regulation. RNA-seq and bioinformatics analysis were used to validate lncRNA-UCL as potential novel target molecule, which was significantly downregulated in DSS-induced mice and upregulated in IL-22-treated mice.

In vitro experiments exhibited that silencing of lncRNA-UCL blocked IEC proliferation, suppressed TJ protein expression (claudin-1, occludin-1, ZO-1, and E-cadherin) and enhanced proinflammatory cytokines (TNF-α, IL-1β, and IL-6) expression.

Previous studies have demonstrated that IL-22 can enhance epithelial growth, tissue regeneration, mucosal defense, and elimination of inflammation by activation of the STAT3 [17, 44]. In our study, we found that the phosphorylation level of STAT3 was decreased by DSS. However, IL-22 treatment could somehow rescue activated STAT3. Meanwhile, knockdown of lncRNA-UCL expression was also able to downregulate the phosphorylation of STAT3 in vitro. In terms of a molecular mechanism, we proposed that lncRNA-UCL regulated the epithelial integrity by regulating the expression of TJ proteins via interacting with miR-568, as lncRNA-UCL is predominantly located in the cytoplasmic, which was shown using subcellular fraction assays. Our results verified that DSS caused the upregulation of miR-568 in colitis mice, while treatment with IL-22 attenuated the increase in miR-568 expression. Furthermore, we further confirmed that miR-568 regulated TJ protein expression by directly targeting the 3′-UTR of claudin-1 mRNA. Thus, we can conclude that IL-22 induced lncRNA-UCL upregulation to maintain the claudin-1 mRNA levels by sequestering miR-568, leading to raising intestinal TJ protein expression levels.

Recently, many studies have shown that lncRNAs are incorporated in pre- and posttranscriptional regulation of gene expression. However, very few lncRNAs have been investigated to have a relationship in the regulation of UC or IBD development and progression. DQ786243 was the first reported CD-associated lncRNA, which may cause CD patients’ peripheral blood mononuclear cell upregulation [45]. Elevated expression of H19 in inflamed tissues promoted IEC proliferation, regeneration, and mucosal healing by inhibiting p53 protein, miR-34a, and let-7 gene expression in mice and human patients [27]. Another investigation conducted on mice, human tissue, and a primary organoid model found that H19 suppressed Paneth and goblet cell function and stopped autophagy, resulting in intestinal pathologies [46]. MALAT1 kept intestinal balance by sequestering mir-146b-5p that targeted the AJC proteins, CLDN11, and NUMB [29]. IncRNA-NAIL regulated colitis initiation and progression via sequestering and inactivating Wip1, thereby enhancing NF-κB and p38 activity, which led to inflammation. Additionally, NAIL could be a probable target biomarker for IBD treatment [47].
At present, various kinds of lncRNAs have been discovered and identified through sequencing, and some of them have been confirmed to have the ability of gene expression regulation. In this study, we identified the novel lncRNA-UCL, which was downregulated in DSS-treated mouse colon tissues. However, its expression was elevated by IL-22 treatment. It has been well established that lncRNAs can regulate gene expression through a ceRNA-related mechanism that is located in the cytoplasm. Our data showed that lncRNA-UCL was mainly expressed in cytoplasm of IECs. Subsequently, a RNA pulldown assay was used to verify that lncRNA-UCL could bind to miR-568 in intestinal epithelial cells. Our results confirmed that lncRNA-UCL regulated intestinal epithelial cell apoptosis and proliferation via sequestering miR-568, thereby upregulating the target protein, claudin-1, and other AJC proteins, including occludin-1, ZO-1, and E-cadherin. However, we failed to identify the homolog of lncRNA-UCL in the human genome, which limits the clinical value of our study to some extent. Moreover, miR-568 has rarely been studied. It was found that human miR-568 targets AKT3/mTORC to regulate hepato-cellular carcinoma stemness and response to chemotherapy [48]. It was also found that human miR-568 regulated acute respiratory distress syndrome and ventilator-induced lung injury inflammatory syndromes via targeting pre-B-cell colony-enhancing factor PBEF/NAMPT, implying potential clinical application value [49].

5. Conclusion

We have demonstrated the incredible role of bioactive compound, such as IL-22, in alleviating DSS-induced colitis symptoms via enhancing lncRNA-UCL expression. It can be regulated using TJ protein, and the lncRNA/miR-568/ claudin-1 axis is important for intestinal epithelial cell normal growth.

Data Availability

Data in this study are available from the corresponding author if anyone has reasonable request.

Ethical Approval

This study was conducted in accordance with Declaration of Helsinki principles, and all experiments performed on animals were approved by the Medical Ethics Committee of Shenzhen People’s Hospital, Shenzhen, China.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jun Yao conceived the study and revised the manuscript. Chonghua He and Zehan Chen performed the experiments and analyzed the data. Chonghua He wrote the manuscript. Jialan Huang and Riyun performed the animal experiments and analyzed the data. Jianyao Wang and Lisheng Wang revised the manuscript. Defeng Li performed the sequencing data analysis. All authors read and approved the final version. Chonghua He and Zehan Chen contributed equally to this work.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No. 81800489) and Technical Research and Development Project of Shenzhen (No. JCYJ20210324113215040). We are grateful to the collaboration of all fellows at Department of Gastroenterology, Shenzhen People’s Hospital, Jinan University.

References

[1] S. C. Ng, H. Y. Shi, N. Hamidi et al., “Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies,” Lancet, vol. 390, no. 10114, pp. 2769–2778, 2017.
[2] G. R. D’Haens and S. van Deventer, “25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future,” Gut, vol. 70, no. 7, pp. 1396–1405, 2021.
[3] B. Shen, G. S. Kochhar, U. Navaneethan et al., “Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group,” The Lancet Gastroenterology & Hepatology, vol. 6, no. 6, pp. 482–497, 2021.
[4] E. E. Nyström, B. Martínez-Abad, L. Arike et al., “An inter- crypt subpopulation of goblet cells is essential for colonic mucus barrier function,” Science, vol. 372, no. 6539, article eabb1590, 2021.
[5] A. Kurilshikov, C. Medina-Gómez, R. Bacigalupe et al., “Large-scale association analyses identify host factors influencing human gut microbiome composition,” Nature Genetics, vol. 53, no. 2, pp. 156–165, 2021.
[6] D. Corridoni, A. Antanaviciute, T. Gupta et al., “Single-cell atlas of colonic CDB8(+) T cells in ulcerative colitis,” Nature Medicine, vol. 26, no. 9, pp. 1480–1490, 2020.
[7] H. S. De Souza, C. Fiocchi, and D. Ilipoulos, “The IBD inter- actome: an integrated view of aetiology, pathogenesis and ther- apy,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 12, pp. 739–749, 2017.
[8] A. N. Ananthakrishnan, G. G. Kaplan, and S. C. Ng, “Chang- ing global epidemiology of inflammatory bowel diseases: sus- taining health care delivery into the 21st century,” Clinical Gastroenterology and Hepatology, vol. 18, no. 6, pp. 1252–1260, 2020.
[9] S. W. Syversen, G. L. Goll, K. K. Jørgensen et al., “Effect of ther- apeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial,” JAMA, vol. 325, no. 17, pp. 1744–1754, 2021.
[10] A. Salas, C. Hernandez-Rocha, M. Duijvestein et al., “JAK-STAT pathway targeting for the treatment of inflammatory bowel disease,” Nature Reviews Gastroenterology & Hepatology, vol. 17, no. 6, pp. 323–337, 2020.
[11] X. Tong, Y. Zheng, Y. Li, Y. Xiong, and D. Chen, “Soluble ligands as drug targets for treatment of inflammatory bowel
disease,” Pharmacology & Therapeutics, vol. 226, article 107859, 2021.

[12] M. R. Spalinger, A. Sayoc-Becerra, C. Orduokhanian et al., “The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions,” Journal of Crohn’s and Colitis, vol. 15, no. 3, pp. 471–484, 2021.

[13] B. Bernshtein, C. Curato, M. Ioannou et al., “IL-23-producing IL-10Ralpha-deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response,” Science Immunology, vol. 4, no. 36, article eaau6571, 2019.

[14] J. A. Dudakov, A. M. Hanash, and M. R. van den Brink, “Interleukin-22: immunobiology and pathology,” Annual Review of Immunology, vol. 23, pp. 747–785, 2015.

[15] W. Ouyang, S. Rutz, N. K. Crellin, P. A. Valdez, and S. G. Hymowitz, “Regulation and functions of the IL-10 family of cytokines in inflammation and disease,” Annual Review of Immunology, vol. 29, pp. 71–109, 2011.

[16] Q. Hou, L. Ye, H. Liu et al., “Lactobacillus accelerates IScs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22,” Cell Death & Differentiation, vol. 25, no. 9, pp. 1657–1670, 2018.

[17] G. Pickert, C. Neufert, M. Leppkes et al., “STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing,” Journal of Experimental Medicine, vol. 206, no. 7, pp. 1465–1472, 2009.

[18] K. Sugimoto, A. Ogawa, E. Mizoguchi et al., “IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 534–544, 2008.

[19] C. L. Zindl, J. F. Lai, Y. K. Lee et al., “IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis,” Proceedings of the National Academy of Sciences, vol. 110, no. 31, pp. 12768–12773, 2013.

[20] M. E. Keir, T. Yi, T. T. Lu, and N. Ghilardi, “The role of IL-22 in intestinal health and disease,” Journal of Experimental Medicine, vol. 217, no. 3, article e20192195, 2020.

[21] B. Pan, D. Wang, L. Li et al., “IL-22 accelerates thymus regeneration via Stat3/Mcl-1 and decreases chronic graft-versus-host disease in mice after allotransplants,” Biology of Blood and Marrow Transplantation, vol. 25, no. 10, pp. 1911–1919, 2019.

[22] Y. Zhu, T. Shi, X. Lu et al., “Fungal-induced glycolysis in macrophages promotes colon cancer by enhancing innate lymphoid cell secrion of IL-22,” The EMBO Journal, vol. 40, no. 11, article e105320, 2021.

[23] T. Arshad, F. Mansur, R. Palek, S. Manzoor, and V. Liska, “A double edged sword role of interleukin-22 in wound healing and tissue regeneration,” Frontiers in Immunology, vol. 11, article 2148, 2020.

[24] A. H. Mirza, C. H. Berthelsen, S. E. Seemann et al., “Transcriptional landscape of IncRNAs in inflammatory bowel disease,” Genome Medicine, vol. 7, no. 1, pp. 1–22, 2015.

[25] X. Han, S. Huang, P. Xue et al., “IncRNA PTPRE-AS1 modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE,” Science Advances, vol. 5, no. 12, article eaax9230, 2019.

[26] Q. Zhang, T. C. Chao, V. S. Patil et al., “The long noncoding RNA ROCK1 regulates inflammatory gene expression,” The EMBO Journal, vol. 38, no. 8, article e100041, 2019.

[27] H. Geng, H. F. Bu, F. Liu et al., “In inflamed intestinal tissues and epithelial cells, interleukin 22 signaling increases expression of H19 long noncoding rna, which promotes mucosal regeneration,” Gastroenterology, vol. 155, no. 1, pp. 144–155, 2018.

[28] L. Xiao, J. Wu, J. Y. Wang et al., “Long noncoding RNA uc.173 promotes renewal of the intestinal mucosa by inducing degradation of microRNA 195,” Gastroenterology, vol. 154, no. 3, pp. 599–611, 2018.

[29] Y. Li, L. Zhu, P. Chen et al., “MALAT1 maintains the intestinal mucosal homeostasis in Crohn’s disease via the mir-146b-5p-CLDN11/NUMB pathway,” Journal of Crohn’s and Colitis, vol. 15, no. 9, pp. 1542–1557, 2021.

[30] H. Lee, Y. S. Son, M. O. Lee et al., “Low-dose interleukin-2 alleviates dextran sodium sulfate-induced colitis in mice by recovering intestinal integrity and inhibiting AKT-dependent pathways,” Theranostics, vol. 10, no. 11, pp. 5048–5063, 2020.

[31] C. Li, Y. Zhou, P. Rychahou et al., “SIRT2 contributes to the regulation of intestinal cell proliferation and differentiation,” Cellular and Molecular Gastroenterology and Hepatology, vol. 10, no. 1, pp. 43–57, 2020.

[32] K. Parikh, A. Antanaviciute, D. Fawkner-Corbett et al., “Colonic epithelial cell diversity in health and inflammatory bowel disease,” Nature, vol. 567, no. 7746, pp. 49–55, 2019.

[33] E. Mennillo, X. Yang, M. Paszek, J. Auwerx, C. Benner, and S. Chen, “NCoR1 protects mice from dextran sodium sulfate-induced colitis by guarding colonic crypt cells from luminal insult,” Cellular and Molecular Gastroenterology and Hepatology, vol. 10, no. 1, pp. 133–147, 2020.

[34] Z. Cai, J. J. Kotzin, B. Ramdas et al., “Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis,” Cell Stem Cell, vol. 23, no. 6, pp. 833–849, 2018.

[35] M. K. Atianand, W. Hu, A. T. Satpathy et al., “A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation,” Cell, vol. 165, no. 7, pp. 1672–1685, 2016.

[36] D. W. Thomson and M. E. Dinger, “Endogenous microRNA sponges: evidence and controversy,” Nature Reviews Genetics, vol. 17, no. 5, pp. 272–283, 2016.

[37] F. Rashid, A. Shah, and G. Shan, “Long non-coding RNAs in the cytoplasm,” Genomics Proteomics Bioinformatics, vol. 14, no. 2, pp. 73–80, 2016.

[38] S. Devrieze, V. Eeckhaut, A. Geirnaert et al., “Reduced mucosa-associated Butyricicoccus activity in patients with ulcerative colitis correlates with aberrant claudin-1 expression,” Journal of Crohn’s and Colitis, vol. 11, no. 2, pp. 229–236, 2017.

[39] E. C. Martens, M. Neumann, and M. S. Desai, “Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier,” Nature Reviews Microbiology, vol. 16, no. 8, pp. 457–470, 2018.

[40] J. M. Allaire, S. M. Crowley, H. T. Law, S. Y. Chang, H. J. Ko, and B. A. Vallance, “The intestinal epithelium: central coordinator of mucosal immunity,” Trends in Immunology, vol. 39, no. 9, pp. 677–696, 2018.

[41] P. Y. Tsai, B. Zhang, W. Q. He et al., “IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance,” Cell Host Microbe, vol. 21, no. 6, pp. 671–681, 2017.

[42] B. Wang, J. H. Lim, T. Kajikawa et al., “Macrophage beta2-integrins regulate IL-22 by ILC3s and protect from lethal...
Citrobacter rodentium-induced colitis,” *Cell Reports*, vol. 26, no. 6, pp. 1614–1626, 2019.

[43] Y. Wang, J. B. Mummm, R. Herbst, R. Kolbeck, and Y. Wang, “IL-22 increases permeability of intestinal epithelial tight junctions by enhancing claudin-2 expression,” *The Journal of Immunology*, vol. 199, no. 9, pp. 3316–3325, 2017.

[44] C. A. Lindemans, M. Calafiore, A. M. Mertelsmann et al., “Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration,” *Nature*, vol. 528, no. 7583, pp. 560–564, 2015.

[45] Y. Q. Qiao, M. L. Huang, A. T. Xu, D. Zhao, Z. H. Ran, and J. Shen, “LncRNA DQ786243 affects Treg related CREB and Foxp3 expression in Crohn’s disease,” *Journal of Biomedical Science*, vol. 20, pp. 1–7, 2013.

[46] T. X. Yu, H. K. Chung, L. Xiao et al., “Long noncoding RNA H19 impairs the intestinal barrier by suppressing autophagy and lowering Paneth and goblet cell function,” *Cellular and Molecular Gastroenterology and Hepatology*, vol. 9, no. 4, pp. 611–625, 2020.

[47] S. C. Akıncılar, L. Wu, Q. F. Ng et al., “NAIL: an evolutionarily conserved IncRNA essential for licensing coordinated activation of p38 and NFkappaB in colitis,” *Gut*, vol. 70, no. 10, pp. 1857–1871, 2020.

[48] G. Shu, H. Su, Z. Wang et al., “LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3,” *Journal of Experimental & Clinical Cancer Research*, vol. 40, no. 1, pp. 1–13, 2021.

[49] D. M. Adyshev, V. R. Elangovan, N. Moldobaeva, B. Mapes, X. Sun, and J. G. N. García, “Mechanical stress induces pre-B-cell colony-enhancing factor/NAMPT expression via epigenetic regulation by miR-374a and miR-568 in human lung endothelium,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 50, no. 2, pp. 409–418, 2014.